Literature DB >> 226379

Binding to alpha-adrenergic receptors: differential pharmacological potencies and binding affinities of benzodioxanes.

H Kapur, B Rouot, S H Snyder.   

Abstract

We have compared the influence of a series of benzodioxane alpha-adrenergic antagonists on 3H-WB-4101 and 3H-clonidine binding to alpha-receptor sites in the brain and peripheral tissues with their pharmacological properties. The drug specificity of 3H-WB-4101 binding is quite similar in central and peripheral tissues. Pharmacological potencies of benzodioxanes at postsynaptic alpha-receptors in the rat vas deferens correlate with potencies at 3H-WB-4101 but not at 3H-clonidine binding sites. These findings suggest pharmacological effects of these drugs are mediated by "alpha-1 postsynaptic receptors" labeled by 3H-WB-4101. For several benzodioxanes absolute pharmacological potencies at postsynaptic alpha-receptors of the rat vas deferens are substantially less than their potencies at 3H-WB-4101 sites. The potencies of benzodioxane analogues at 3H-clinidine binding sites are similar to their pharmacological potencies at presynaptic autoreceptors in the rat vas deferens.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226379     DOI: 10.1016/0014-2999(79)90494-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Adrenoceptor blocking properties of atropine-like agents anisodamine and anisodine on brain and cardiovascular tissues of rats.

Authors:  D R Varma; T L Yue
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

2.  alpha-adrenergic antagonists as possible calcium channel inhibitors.

Authors:  D Atlas; M Adler
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

3.  Regulation of alpha 1-adrenoceptors in the cerebral cortex of the rat by thyroid hormones.

Authors:  G Gross; O E Brodde; H J Schümann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.